6 stories mentioning NSE:MANKINDUpdated 15d ago
Every FINWIRES story that references NSE:MANKIND, newest first.
Mankind Pharma (BOM:543904, NSE:MANKIND) completed the sale of its entire stake in Broadway Hospitality Services for 490 million rupees in cash, according to a Monday stock exchange filing.The transaction completes the sale of the unit to AKRK Projects and Partners, which Mankind Pharma announced earlier this month as part of its strategy to divest non-core assets.
Mankind Pharma (BOM:543904, NSE:MANKIND) approved the sale of its wholly owned subsidiary, Broadway Hospitality Services, according to an exchange filing Saturday.The company will sell its entire stake in Broadway to AKRK Projects and Partners for 4.90 billion rupees, subject to closing adjustments.The transaction is expected to be completed within 90 days as part of Mankind Pharma's strategy to divest non-core assets.Separately, Mankind Pharma approved the incorporation of a wholly owned subsidiary in the Netherlands as a special purpose vehicle to hold R&D investments and support business development in niche therapies.The company plans to invest up to 5 million euros in the Dutch unit in one or more tranches to fund its setup, operations, procurement, and future investments.
Mankind Lifesciences, a wholly-owned subsidiary of Mankind Pharma (NSE:MANKIND, BOM:543904), has acquired the remaining 10% stake it did not already own in Upakarma Ayurveda for 7.50 million Indian rupees, according to a Tuesday filing to the Indian stock exchanges.Mankind Lifesciences already held 90% stake in Upakarma Ayurveda, and has acquired the remaining 10% stake of Upakarma from Kaushcorp Media.Following the acquisition, Upakarma has become a wholly-owned subsidiary of Mankind Lifesciences and a step-down subsidiary of the company.Upakarma sells ayurvedic, herbal, and nutraceutical products.
Mankind Pharma (NSE:MANKIND, BOM:543904) consolidated profit attributable to equity holders climbed to 5.54 billion Indian rupees in the fiscal fourth quarter from 4.21 billion rupees a year ago, according to an Indian bourse filing on Tuesday.Shares of the company rose 3% in Wednesday's trade.Earnings per share for the quarter ended March 31 increased to 13.41 rupees from 10.18 rupees a year earlier, the filing said.The pharmaceutical company's revenue from operations in fiscal Q4 rose year on year to 34.4 billion rupees from 30.8 billion rupees.
CARE Ratings assigned AA+ rating to Mankind Pharma's (NSE:MANKIND, BOM:543904) long-term bank facilities and A1+ rating to the short-term bank facilities of the pharmaceutical company, according to an Indian bourse filing on Wednesday.Shares of the company rose nearly 3% in Thursday's trade.The rating outlook is stable.
